Specialized in cardiac electrophysiology, PhysioStim put forward GLP safety pharmacology studies to evaluate your compounds on the risk of QT interval prolongation.
In accordance with ICHS7B &S7A guidelines, we propose to Pharmaceutical and Biotechs companies in vitro models based on:
-human ion channels assays
-Action potential recordings
-Isolated Langendorff perfused heart
More than 480 studies have been performed in house, including 35% GLP studies (more than 100 GLP hERG assays).